Accueil
mcv4
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

4.8 (234) · € 21.99 · En Stock

A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine

Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme - ScienceDirect

An evaluation of emerging vaccines for childhood meningococcal disease, BMC Public Health

Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial - The Lancet Infectious Diseases

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

Microorganisms, Free Full-Text

Vaccines, Free Full-Text

ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs - Susana Otero-Romero, Christine Lebrun-Frénay, Saúl Reyes, Maria Pia Amato, Magda Campins